Advertisement
Screener

Minerva Neurosciences, Inc. (NERV) Amortization of Leased Asset

1.6 / 5 stars · 17/54 Roast Me

Minerva Neurosciences, Inc. Amortization of Leased Asset

Minerva Neurosciences, Inc. (NERV) reported Amortization of Leased Asset of $101.79 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-08.

Discontinued › Expense Statement › Operating Expenses

us-gaap:AmortizationOfLeasedAsset · last filed 2021-11-08

  • Minerva Neurosciences, Inc. amortization of leased asset for the quarter ending 2021-09-30 was $14.94K, a 63.16% decline year-over-year.
  • Minerva Neurosciences, Inc. amortization of leased asset for the quarter ending 2021-06-30 was $44.01K, a 11.48% increase year-over-year.
  • Minerva Neurosciences, Inc. amortization of leased asset for the quarter ending 2021-03-31 was $42.83K, a 11.40% increase year-over-year.
  • Minerva Neurosciences, Inc. amortization of leased asset for the quarter ending 2020-12-31 was $41.68K, a 11.32% increase year-over-year.
  • Minerva Neurosciences, Inc. amortization of leased asset for fiscal 2020 was $160.17K, a 11.20% increase from fiscal 2019.
  • Minerva Neurosciences, Inc. amortization of leased asset for fiscal 2019 was $144.04K.
Period endAmortization of Leased Asset 3 monthAmortization of Leased Asset 6 monthAmortization of Leased Asset 9 monthAmortization of Leased Asset 12 month
2021-09-30$14.94K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$58.95K
derived: sum of 2 quarters · filed 2021-11-08
$101.79K
10-Q · filed 2021-11-08
$143.47K
derived: sum of 4 quarters · filed 2021-11-08
2021-06-30$44.01K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02
$86.85K
10-Q · filed 2021-08-02
$128.53K
derived: sum of 3 quarters · filed 2021-08-02
$169.08K
derived: sum of 4 quarters · filed 2021-11-08
2021-03-31$42.83K
10-Q · filed 2021-05-12
$84.51K
derived: sum of 2 quarters · filed 2021-05-12
$125.07K
derived: sum of 3 quarters · filed 2021-11-08
$164.55K
derived: sum of 4 quarters · filed 2021-11-08
2020-12-31$41.68K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08
$82.23K
derived: sum of 2 quarters · filed 2021-11-08
$121.72K
derived: sum of 3 quarters · filed 2021-11-08
$160.17K
10-K · filed 2021-03-08
2020-09-30$40.55K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$80.04K
derived: sum of 2 quarters · filed 2021-11-08
$118.49K
10-Q · filed 2021-11-08
$155.93K
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30$39.48K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02
$77.93K
10-Q · filed 2021-08-02
$115.37K
derived: sum of 3 quarters · filed 2021-08-02
$151.83K
derived: sum of 4 quarters · filed 2021-08-02
2020-03-31$38.45K
10-Q · filed 2021-05-12
$75.89K
derived: sum of 2 quarters · filed 2021-05-12
$112.35K
derived: sum of 3 quarters · filed 2021-05-12
$147.87K
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31$37.44K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08
$73.90K
derived: sum of 2 quarters · filed 2021-03-08
$109.42K
derived: sum of 3 quarters · filed 2021-03-08
$144.04K
10-K · filed 2021-03-08
2019-09-30$36.46K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
$71.98K
derived: sum of 2 quarters · filed 2020-11-02
$106.60K
10-Q · filed 2020-11-02
2019-06-30$35.52K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03
$70.14K
10-Q · filed 2020-08-03
2019-03-31$34.62K
10-Q · filed 2020-05-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Annexon, Inc. (ANNX)United States$0.147B-4.22
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91